Close Menu

BARDA

Rick Bright, the former BARDA director, updates his whistleblower complaint to include allegations of ongoing retaliation, CBS News reports.

The firm expects to validate its test as a triage tool to identify SARS-CoV-2 patients at risk of sepsis and pursue US FDA Emergency Use Authorization.

The New York Times reports that a federal watchdog group has recommended Rick Bright be reinstated to his former post during its investigation of his whistleblower claims.

The Washington Post reports former BARDA Director Rick Bright alleges in a whistleblower complaint he was removed from his post for trying to "prioritize science and safety over political expediency."

The added funds will be used by Tangen to develop a molecular diagnostic platform to detect anthrax in the bloodstream and develop infectious disease tests.

Starting in late May, Hologic expects to begin producing at least 1 million Aptima SARS-CoV-2 assays per week, BARDA noted.

Backed by BARDA, Merck and Institute for Systems Biology are studying multiomic data to understand infection pathways and find biomarkers for symptom risk.

Forced Out

Former BARDA chief Rick Bright tells the New York Times he was forced out because he pushed for strict testing of a coronavirus treatment touted by President Donald Trump.

Left BARDA Behind

Stat News reports Rick Bright is no longer the head of the Biomedical Advanced Research and Development Authority.

The test is expected to run on Tangen's GeneSpark nucleic acid amplification platform and achieve a CLIA waiver for use in doctors' offices.

Pages

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.